New Vitiligo Treatment 2025

New Vitiligo Treatment 2025. Abbvie recently announced that its phase 2b study investigating upadacitinib (rinvoq) for the treatment of adults with nonsegmental vitiligo met the primary end point of percent change from baseline in the facial vitiligo. Panelists discuss how their clinical experiences with topical ruxolitinib are shaping new treatment paradigms for vitiligo, while also addressing challenges related to medication access.


New Vitiligo Treatment 2025

Individualized treatment is appropriate according to the location, clinical presentation and the presence of disease activity. “hands in particular don’t seem to respond to any of the.

New Vitiligo Treatment 2025 Images References :